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To determine the long-term health and function of
transplanted dopamine neurons in Parkinson’s dis-
ease (PD) patients, the expression of dopamine
transporters (DATs) and mitochondrial morphology
were examined in human fetal midbrain cellular
transplants. DAT was robustly expressed in trans-
planted dopamine neuron terminals in the reinner-
vated host putamen and caudate for at least 14 years
after transplantation. The transplanted dopamine
neurons showed a healthy and nonatrophied
morphology at all time points. Labeling of the mito-
chondrial outer membrane protein Tom20 and a-syn-
uclein showed a typical cellular pathology in the
patients’ own substantia nigra, which was not
observed in transplanted dopamine neurons. These
results show that the vast majority of transplanted
neurons remain healthy for the long term in PD
patients, consistent with clinical findings that fetal
dopamine neuron transplants maintain function for
up to 15–18 years in patients. These findings are
critically important for the rational development of
stem-cell-based dopamine neuronal replacement
therapies for PD.INTRODUCTION
There is a need to understand how transplanted neurons can
survive despite ongoing disease processes in the brains of pa-
tients with Parkinson’s disease (PD). Currently, there is some
controversy surrounding the neural transplantation field and
neuroscience research regarding interactions between poten-
tially pathological toxic proteins as a cause of neurodegenera-
tion, and the concept of ‘‘disease spread’’ from cell to cell (Des-
plats et al., 2009; Isacson and Mendez, 2010). The accumulation
of Lewy-body-like inclusions in some transplanted fetal dopa-
mine neurons after long-term survival (over a decade) in the PD
brain has been described (Cooper et al., 2009; Kordower et al.,
2008; Kurowska et al., 2011; Li et al., 2008). Such pathology is
a rare occurrence, with only a very low frequency (1%) ofCgrafted neuromelanin-containing neurons in cell suspension
grafts exhibiting signs of a-synuclein pathology even 22 years
after grafting (Kurowska et al., 2011). These isolated cell inclu-
sions are not observed in all patients (Mendez et al., 2008) and
are usually found in less than 1%–5% of transplanted neurons
depending on the transplantation method used, and clinical
and postmortem data indicate that this rare pathology does
not affect overall graft function (Cooper et al., 2009; Isacson
and Mendez, 2010). It has been suggested that such Lewy-
body-like pathology is a product of protein transfer from the
parkinsonian host brain to the transplanted fetal cells (Kurowska
et al., 2011). However, a-synuclein pathology is not definitive for
PD, and incidental a-synuclein pathology has also been reported
in the normal aging brain, with frequencies of 8%–22.5% in
normal aging and up to 34.8% in centenarians (Ding et al.,
2006; Klos et al., 2006; Mikolaenko et al., 2005; Saito et al.,
2004; Wakisaka et al., 2003). Experimental paradigms of oxida-
tive stress (e.g., rotenone exposure) or neuroinflammation can
also induce a-synuclein accumulation in dopamine neurons
(Gao et al., 2008; Sherer et al., 2003).
Recent results from postmortem examinations of fetal ventral
mesencephalic grafts in PD patients suggested that dopamine
transporters (DATs) are downregulated in the transplanted dopa-
mine neurons (Kordower et al., 2008; Kurowska et al., 2011), and
that such changes (which also include reduction of the dopamine
neuron phenotypic marker tyrosine hydroxylase [TH]) are indica-
tive of neuronal dysfunction and PD pathophysiological changes
in the transplanted neurons. Since a cell therapy approach holds
considerable promise as a therapeutic strategy for PD (C.R.
Freed et al., 2013, Soc. Neurosci., conference; Kefalopoulou
et al., 2014; Ma et al., 2010; Mendez et al., 2005; Politis et al.,
2010, 2012), it is important to address the status of transplanted
fetal dopamine cells in more detail. In previous studies, we re-
ported surgical, clinical, and histopathological data obtained in
five patients with advanced idiopathic PD who had received
intracerebral transplantation of fetal dopaminergic cell suspen-
sion grafts 4–14 years earlier (Cooper et al., 2009; Mendez
et al., 2005, 2008). In those studies, therapeutic improvements
were seen without clinical side effects, such as off-period dyski-
nesias. Postmortem examinations demonstrated that grafted
dopaminergic neurons survived for up to 14 years posttransplan-
tation. In the current study, we examined DAT expression as a
measure of neuronal function, and the mitochondrial marker
Tom20 (translocase of outer mitochondrial membrane 20 kDa)ell Reports 7, 1755–1761, June 26, 2014 ª2014 The Authors 1755
to assess mitochondrial morphology, to further understand the
long-term phenotypical characteristics of the transplanted
dopamine neurons and potential effects of the aging of
transplants.
RESULTS
Dopamine Transporter Localization and Expression
in Transplanted Fetal Dopamine Neurons
In the present study, we assessed DAT immunostaining in 4- to
14-year-old grafts in five patients from our previously published
series (Mendez et al., 2005, 2008) in order to further understand
the long-term phenotypical characteristics of the transplanted
dopamine neurons and potential effects of the aging of
transplants.
We conducted immunofluorescence staining for DAT using a
monoclonal antibody that recognizes the N terminus of DAT
(Miller et al., 1997), and performed colabeling with a TH antibody
to label dopaminergic neurons and fibers. A general assessment
of the integrity of the grafted TH-immunoreactive neurons in all
patients revealed cells with a healthy appearance, including a
robust cell soma and absence of signs of atrophy (Figures 1A–
1C, 1F–1H, 1K–1M, and 1P–1R). In two independent patients
at 4 years posttransplantation (Figures 1A–1J), an examination
of DAT/TH immunostaining at low magnification (Figures 1A
and 1F) showed dense DAT and TH expression in the reinner-
vated putamen and caudate in areas both near to and farther
away from the graft. Although DAT was also expressed in the
grafted cell soma, the intense punctate staining pattern in the re-
innervated areas was most striking (Figures 1B and 1G). This
expression, consistent with that of synaptic proteins, was easily
observed at high magnification (Figures 1C, 1D, 1H, and 1I)
where DAT was localized along TH-immunoreactive fibers.
To determine whether DAT expression was maintained in the
long term, we examined DAT immunolabeling in transplanted
neurons at 9 years and 14 years posttransplantation (Figures
1K–1T). As also seen at the younger time points, a robust punc-
tate expression in the reinnervated striatum was observed (Fig-
ures 1K–1M and 1P–1R) and higher-magnification imaging
verified the coexpression of DAT puncta along TH-immunoreac-
tive dopaminergic fibers (Figures 1N and 1S). The intensity of
DAT immunofluorescence was quantified in the reinnervated
putamen at 4–14 years after transplantation (Figure S1) and
compared with DAT labeling intensity in the contralateral (non-
transplanted) putamen from subject 2. As expected, very low
levels of DAT labeling in the nontransplanted parkinsonian puta-
men were observed, consistent with the severe loss of DAT
expression in the putamen in PD (Miller et al., 1997). In contrast,
at 4, 9, and 14 years after transplantation, DAT expression was
significantly increased within the grafted putamen.
Parallel control immunostainings in which the primary anti-
bodies were omitted showed no immunoreactivity of DAT or
TH (data not shown). To further confirm the specificity of the
DAT labeling observed in the reinnervated putamen and
caudate, we also examined DAT immunolabeling in adjacent
anatomical regions on the same tissue sections (see Figure 1).
As expected, in the lateral and medial globi pallidi, which are re-
gions that receive comparatively little dopaminergic innervation1756 Cell Reports 7, 1755–1761, June 26, 2014 ª2014 The Authorsand normally exhibit little DAT expression in the human brain (Cil-
iax et al., 1999), we observed weak DAT immunolabeling and a
sharp boundary from high to low DAT and TH expression (Fig-
ures 1E, 1J, 1O, and 1T).
Mitochondrial Localization and Expression
in Transplanted Fetal Dopamine Neurons
Tom20 was used to label mitochondria in grafted neurons and
also in the host substantia nigra and globus pallidus. In the re-
maining substantia nigra TH-immunoreactive neurons from PD
patients (subjects 2, 5, and 6; Figures 2A, 2A’, 2D, 2D’, 2G,
and 2G’), Tom20 labeling often appeared intensely labeled in
the cell soma, with accumulation in the perinuclear area and little
immunostaining in the axon and processes. In neurons cos-
tained with Tom20 and a-synuclein, the host patient’s substantia
nigra showed Lewy bodies and variable or reduced distribution
of Tom20-stained mitochondria (Figure 3A). In grafted TH-immu-
noreactive neurons at 4 years posttransplantation (Figures 2B
and 2B’), Tom 20 immunostaining was robust in the perikarya
and neuronal processes, similar to what was observed in the
normal brain. At 9 and 14 years posttransplantation, Tom20
labeling was generally less intense in the grafted TH-immunore-
active neurons (Figures 2E, 2E’, 2H, and 2H’) compared with the
Tom20 staining pattern observed in subject 2 at 4 years post-
transplantation; however, there was no abnormal accumulation
ofmitochondria in the cell soma aswas observed in the host sub-
stantia nigra. The localization of Tom20 in neurons within the
host medial globus pallidus (Figures 2C, 2F, and 2I) exhibited a
homogeneous localization throughout the cell soma and pro-
cesses, and showed no evidence of abnormal perinuclear accu-
mulation as was observed in the patients’ own substantia nigra.
In neurons within the transplants costained with Tom20 and
a-synuclein, a normal distribution of Tom20 staining was
observed in the absence of Lewy bodies (Figures 3B–3D).
DISCUSSION
Efficacious fetal ventral mesencephalic grafts can reduce both
PD motor symptoms and levodopa-induced dyskinesia for
many years, and can reduce or negate the requirement for dopa-
mine replacement therapy. Months to years are required for the
newly replaced dopaminergic neurons to mature, integrate into
the host brain, and function (Barker et al., 2013), and most fetal
ventral mesencephalic cell transplants provide improvement in
PD motor symptoms starting at 1 year after transplantation
(Evans et al., 2012). However, successful transplants can survive
and function for many years. Recent studies by Kefalopoulou
et al. (2014) and Politis et al. (2010, 2012) described two patients
who were still improving (as shown by PET neuroimaging of
dopamine uptake and reduction of the Unified Parkinson’s Dis-
ease Rating Scale score) more than 18 years after they had un-
dergone transplantation of fetal ventral mesencephalic cells.
The study presented here shows long-term graft survival in PD
patients with maintained DAT localization along TH-immunore-
active axons in the reinnervated striatum, indicating functional
dopaminergic neurons. Abnormalities in mitochondrial localiza-
tion, as indicated by accumulation in the cell soma in dopami-
nergic neurons in the host substantia nigra, were not observed
Figure 1. Dopamine Transporter Expression in the Reinnervated Putamen at 4–14 Years Posttransplantation
(A–T) Double immunolabeling for DAT (green) and TH (red) in subjects 1 (A–E; graft survival of 4 years), 2 (F–J; graft survival of 4 years), 4 (K–O; graft survival of 9
years), and 5 (P–T; graft survival of 14 years). Panels (A), (F), (K), and (P) show a low-magnification composite for each subject to illustrate the grafted cell bodies
and adjacent reinnervated putamen. Successively higher-magnification images are illustrated in (B)–(D), (G)–(I), (L)–(N), and (Q)–(S). Boxed areas represent the
image shown in the subsequent panel. Panels (E), (J), (O), and (T) show a low-magnification composite of the patient’s putamen and adjacent external segment of
the globus pallidus. DAT immunostaining shows a robust punctate localization along dopaminergic (TH-immunoreactive) fibers in the reinnervated putamen and
caudate in all grafts, even up to 14 years posttransplantation. In addition, the transplanted dopamine neurons show a healthy and nonatrophied morphology.
Parallel control immunostainings in which the primary antibodies were omitted showed no immunoreactivity of DAT or TH (data not shown). To further confirm the
specificity of the DAT labeling observed in the reinnervated putamen and caudate, we also examined DAT immunolabeling in adjacent anatomical regions on the
same tissue sections. As expected, in the lateral and medial globus pallidi, which are regions that receive comparatively little dopaminergic innervation and
normally exhibit little DAT expression in the human brain (Ciliax et al., 1999), we observed weak DAT immunolabeling and a sharp boundary from high to low DAT
and TH expression (E, J, O, and T). We also performed immunostaining in the substantia nigra of each patient and confirmed the loss of both DAT and TH
immunoreactivity (data not shown). g, graft; h, host; GPe, globus pallidus externa. Scale bars, 400 mm in (A), (E), (F), (J), (K), (O), (P), and (T); 100 mm in (B), (G), (L),
and (Q); 50 mm in (C), (H), (M), and (R); and 20 mm in (D), (I), (N), and (S). See also Figure S1.in grafted neurons. These data are consistent with clinical and
neuroimaging data showing stable dopamine cell survival and
function more than 18 years after surgery (Kefalopoulou et al.,
2014; Politis et al., 2010, 2012).
DAT is a plasma membrane protein located on presynaptic
dopamine nerve terminals, where it is responsible for the termi-
nation of dopamine transmission and reuptake of dopamine
released into the synaptic cleft back into the presynaptic dopa-Cmine neurons (Nirenberg et al., 1997). DAT is highly concentrated
in the striatum in nigrostriatal dopaminergic projections and is
localized to the plasma membranes of axonal varicosities and
terminals containing synaptic vesicles (Nirenberg et al., 1997),
consistent with its involvement in dopaminergic synaptic trans-
mission in the striatum. Recent studies have suggested that in
human PD patients, DAT expression in transplanted fetal dopa-
mine ventral mesencephalic neurons is downregulated overell Reports 7, 1755–1761, June 26, 2014 ª2014 The Authors 1757
Figure 2. Mitochondrial Phenotype in Transplanted Fetal Dopamine Neurons at 4–14 Years Posttransplantation
(A–I’) Double immunolabeling for translocase of outer mitochondrial membranes 20 kDa (Tom20, green) and TH (red) in the host substantia nigra (left panels),
grafted dopamine neurons (middle panels), and host globus pallidus (right panels) in subject 2 (A, A’, B, B’, C, and C’; graft survival of 4 years), subject 6 (D, D’, E,
E’, F, and F’; graft survival of 9 years), and subject 5 (G, G’, H, H’, I, and I’; graft survival of 14 years). Panels (A’)–(I’) show single-channel Tom20 labeling from
corresponding panels (A)–(I). In dopamine (TH-immunoreactive) neurons from the patients’ own substantia nigra, Tom20 labeling often appeared intensely
labeled in the cell soma, with accumulation in the perinuclear area (arrows) and little immunostaining in the dopaminergic axons and processes (A, A’, D, D’, G, and
G’). In grafted TH-immunoreactive neurons at 4 years posttransplantation, Tom20 labelingwas robust in the perikarya and neuronal processes (B and B’). At 9 and
14 years posttransplantation, Tom20 labeling was generally less intense in the grafted TH-immunoreactive neurons (E, E’, H, and H’) compared with the Tom20
staining pattern observed in subject 2 at 4 years posttransplantation; however, there was no abnormal accumulation of mitochondria in the cell soma as was
observed in the host substantia nigra. No perinuclear accumulation or fragmentation of Tom20-labeled mitochondria was observed in the host globus pallidus
(C, C’, F, F’, I, and I’). Scale bar, 50 mm.time, and that this is indicative of PD processes within the graft
and loss of function of the grafted dopamine neurons (Kordower
et al., 2008; Kurowska et al., 2011). In these studies, the authors
used immunolabeling for DAT and subsequent light microscopy.
Surprisingly, in older grafts, these studies described only the
expression of DAT in the grafted cell soma, with no reported
analysis or discussion of the expression and localization of
DAT in the dopamine neuron fibers reinnervating the putamen.
In the current study, we also noted a qualitative reduction in
the intensity of the DAT signal in the cell soma of the grafted
dopamine neurons over time when we compared grafts at 4, 9,
and 14 years posttransplantation, but it was striking to us that
the punctate DAT expression in the reinnervated putamen and
caudate was maintained, even over a decade posttransplanta-
tion. We previously showed that the extent of DAT labeling in
the caudate and putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP)-lesioned monkeys, as detected by [11C]CFT
PET neuroimaging, is congruent with the number of surviving
dopaminergic fibers (Hantraye et al., 1992). DAT is a marker of
mature dopamine synapse function, and thus our findings of
robust DAT labeling in the putamen of patients analyzed in our
series are indicative of the long-term, continued health and func-
tion of transplanted dopamine neurons. Therefore, based on
DAT expression, we do not find evidence of PD pathophysiolog-1758 Cell Reports 7, 1755–1761, June 26, 2014 ª2014 The Authorsical processes in grafted dopaminergic neurons. Clearly, using
the current transplantation methodology, fetal grafts can result
in dopamine neurons that are clinically functional for the long
term (Barker et al., 2013; Mendez et al., 2005). A previous anal-
ysis of a-synuclein pathology in the same transplant cases
described here (Cooper et al., 2009; Mendez et al., 2008) re-
vealed only one Lewy body in a neuron of a fetal graft in one of
these cases (Cooper et al., 2009). In fetal ventral mesencephalic
transplant cases from other transplant-method series, in which
we have also observed more frequent Lewy body and a-synu-
clein pathology (albeit still <5% of grafted neurons), the overall
morphology in the vast majority of the surviving transplanted
dopaminergic neurons was also unchanged (Cooper et al.,
2009; Kordower et al., 2008). Indeed, it was also reported that
there is no alteration in the expression of VMAT2, another marker
of dopamine presynaptic nerve terminals, in grafted dopamine
neurons over time (Kordower et al., 2008). The current study pro-
vides important additional evidence against the relevance of a
postulated prion-like a-synuclein mechanism for disease propa-
gation. Instead of the concept of a-synuclein spreading from
host to graft to cause dysfunction, the opposite may be true,
i.e., the healthy transplanted cells provide a clearance mecha-
nism for exogenous unfolded proteins. Our present study un-
equivocally demonstrates positive markers of dopamine neuron
Figure 3. Mitochondria Abnormalities Occur Independently of Lewy Body Pathology in Host Neurons and Neither Lewy Body Pathology nor
Mitochondrial Abnormalities Were Found in Transplanted Neurons
(A) Coimmunofluorescence labeling of a-synuclein (red) and the mitochondrial import receptor subunit Tom20 (green) was observed in neurons within the
substantia nigra of PD patient 6. Mitochondria in neurons containing accumulated a-synuclein in the host were either diffusely distributed throughout the
cytoplasm (cell 1) or were dense in appearance (cell 2). Mitochondria were also diffusely distributed in the cytoplasm of cells without Lewy bodies (cell 3).
(B–D) No Lewy body pathology was found in the transplanted neurons of PD patients 2 (B), 5 (C), and 6 (D), and mitochondria were dense throughout the
cytoplasm. m, mitochondria; LB, Lewy body. Scale bar, 50 mm.function and thus provides a further rationale for clinical cell
therapy for PD using stem cell-derived dopamine neuron
equivalents.
We also examined the localization and expression of mito-
chondria in grafted dopaminergic neurons as a possible indica-
tor of increased aging and readout of neuronal function. Mito-
chondrial dynamics, including fission, fusion, and transport,
are crucial for the maintenance of bioenergetic function and pre-
vention of apoptosis (Detmer and Chan, 2007). Mitochondrial
dysfunction is a prominent feature of PD and dopaminergic sub-
stantia nigra neurons are particularly vulnerable to mitochondrial
dysfunction due to their dependence on a high metabolic rate
(Exner et al., 2012). We frequently observed that the remaining
dopaminergic neurons in the host substantia nigra pars com-
pacta contained Tom20-labeled mitochondria that were accu-
mulated in the cell soma, with very little staining or only a frag-
mented staining pattern in neurites. Such a redistribution of
mitochondria has also been observed in pyramidal neurons in
postmortem brains of patients with Alzheimer’s disease, using
antibodies against COX I and mitochondria fusion/fission pro-
teins (Wang et al., 2009). Intracellular mitochondrial distribution
is critical for the functioning of neurons and mitochondrial frag-
mentation, and a reduced localization ofmitochondria in neurites
may reflect disruptions in axonal transport and/or disrupted
mitochondrial fusion/fission. In contrast, in grafted TH-immuno-
reactive neurons at 4 years posttransplantation, the Tom20-
labeled mitochondria displayed a more uniform distribution
throughout the cell soma and neurites, with no indication of frag-
mentation or accumulation in the cell soma. The overall reduced
expression of Tom20-labeled mitochondria that we observed in
grafted dopamine neurons at 9 and 14 years posttransplantation
may reflect an overall reduced mitochondrial biogenesis or
increased mitophagy as a function of accelerated aging in these
neurons. By all current cell-biological accounts, the distribution
of the mitochondrial network we describe is likely more informa-
tive than a total mitochondrial count, which is practically difficult
(if not impossible) to obtain in regular postmortem material.
Furthermore, even if such a method existed, a similar mitochon-
drial mass or number between populations of neurons would notCnecessarily equate with physiologically functional mitochondria
due to heteroplasmia (the coexistence of both faulty and func-
tional mitochondria in the same cell) (Kraytsberg et al., 2006;
Larsson, 2010; Sanders et al., 2014).
The observations of continued DAT expression and normal
mitochondrial cellular distribution at 4–14 years posttransplanta-
tion are consistent with the clinical data and show that implanted
dopamine neurons remain healthy and functional for decades
(C.R. Freed et al., 2013, Soc. Neurosci., conference; Kefalopou-
lou et al., 2014; Politis et al., 2010, 2012). In summary, our post-
mortem examination of tissue from PD patients who had
received fetal ventral mesencephalic cells transplanted as a
cell suspension shows that following long-term graft survival,
DAT localization along TH-immunoreactive axons and fibers is
maintained in the reinnervated striatum, indicating functional
dopaminergic neurons. Abnormalities in mitochondrial localiza-
tion, as indicated by accumulation in the cell soma in dopami-
nergic neurons in the host substantia nigra, were not observed
in grafted neurons. Our data are not consistent with the sugges-
tion that these grafts degenerate over time, and instead show
that there is no cell-biological evidence for such an assertion.
These data support clinical and neuroimaging findings of the
long-lasting functional benefit of dopamine neuron transplanta-
tion in PD patients (C.R. Freed et al., 2013, Soc. Neurosci., con-
ference; Kefalopoulou et al., 2014; Ma et al., 2010; Mendez et al.,
2005; Politis et al., 2010, 2012), and provide an important foun-
dation for the development of future fetal and stem cell-derived
dopamine replacement therapies for PD.EXPERIMENTAL PROCEDURES
Patient Selection
Caudate putamen, globus pallidus, and substantia nigra tissues from five
patients (referred to as subjects 1, 2, 4, 5, and 6) with advanced idiopathic
PD who had undergone fetal tissue transplantation for 4–14 years were exam-
ined in this study. All protocols were approved by institutional review boards.
We previously reported the surgical procedures, neuroimaging data, clinical
outcome, and postmortem histological assessments of the phenotypical char-
acteristics and PD pathophysiological markers in transplanted neurons in this
series of patients (Cooper et al., 2009; Mendez et al., 2005, 2008).ell Reports 7, 1755–1761, June 26, 2014 ª2014 The Authors 1759
Tissue Preparation
At postmortem examination (after a delay of 3–4 hr), the brains were infused
with 2 l of cold 0.1 M phosphate buffer (pH 7.4), followed by 2 l of ice-cold
4% paraformaldehyde in 0.1 M phosphate buffer. The brains were subse-
quently blocked in the coronal plane in 3-cm-thick slabs. The slabs were cry-
oprotected in 30% sucrose in PBS at 4C.
Immunohistochemistry
Sections (40 mm)were stained using immunofluorescence techniques. In order
to maintain consistency of DAT or TOM20 labeling between subjects, immu-
nostainings were performed at the same time and using identical reagents.
DAT labeling was enhanced using a fluorescent streptavidin conjugate as
described below. Sections were rinsed three times for 10 min in PBS, incu-
bated in 10% normal donkey serum (Vector Laboratories) and 0.3% Triton
X-100 in PBS for 60 min, and then incubated with gentle agitation for 48 hr
at 4C in primary antibody (rat anti-DAT, 1:200 [MAB369; Millipore]; sheep
anti-TH, 1:300 [P60101-0, Pel-Freez]; rabbit anti-Tom20, 1:200 [sc-11415;
Santa-Cruz]). For a-synuclein staining, the LB509 antibody (Invitrogen/Life
Technologies) was used at 1:500 dilution. After an additional three 10 min
rinses in PBS, the sections were incubated in fluorescent dye-conjugated sec-
ondary antibodies in PBS for 60 min at room temperature for detection of TH
and Tom20 (Alexa Fluor donkey anti-rabbit/sheep 488/568; 1:500 [Molecular
Probes]). For detection of DAT and a-synuclein, sections were incubated in
a biotinylated secondary antibody (donkey anti-rat/mouse; 1:250; Vector Lab-
oratories) in PBS for 60 min at room temperature, followed by three 10 min
rinses in PBS, and incubation in streptavidin Alexa Fluor 488 (1:500, Molecular
Probes) for 60 min. After rinsing in PBS (three times for 10 min), sections were
mounted onto Superfrost Plus slides and an autofluorescence eliminator re-
agent was applied (Millipore) prior to coverslipping in Mowiol mounting media.
The specificity of DAT, Tom20, TH, and a-synuclein labelingwas confirmed us-
ing stainings in parallel tissue sections from each subject in which the primary
antibody was omitted.
Confocal Microscopy
Immunofluorescence staining was examined with the use of a confocal micro-
scope (LSM510 Meta; Carl Zeiss) at 10, 25, or 1003 magnification. Single or
z-stack images were acquired using a sequential scanning mode with a frame
size of 1,0243 1,024 pixels, and averaging of four frames. The laser intensity,
confocal aperture, photomultiplier voltage, scan speed, image size, filter, and
zoom were kept identical while all images were acquired. For quantification of
DAT labeling, confocal images at 253 magnification (at least five per subject)
were obtained in the reinnervated putamen or in the denervated, nontrans-
planted putamen. The average optical density of DAT immunofluorescence
intensity in each subject was analyzed using ImageJ software (ImageJ 1.44i;
National Institutes of Health).
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2014.05.027.
AUTHOR CONTRIBUTIONS
P.J.H. designed and performed research, analyzed and interpreted data, and
wrote the paper. O.C. designed research and analyzed data. D.S. performed
research. H.R. evaluated data and wrote the paper. I.M. designed and per-
formed research, evaluated data, and wrote the paper. O.I. designed and per-
formed research, analyzed and interpreted data, and wrote the paper.
ACKNOWLEDGMENTS
We thank Dr. Gaynor Smith for helpful discussions, and Eduardo Perez-Torres
and David Ahmadi for technical assistance. This work was supported by the
National Institutes of Health/National Institute of Neurological Disorders and
Stroke P50 (grant NS39793 to O.I.), the Harvard Stem Cell Institute Transla-
tional Neuroscience Fund (to O.I.), the Canadian Institute of Health Research,1760 Cell Reports 7, 1755–1761, June 26, 2014 ª2014 The AuthorsQueen Elizabeth II Health Sciences Centre (to I.M.), The Consolidated
Anti-Aging Foundation (to O.I.), The Poul Hansen Family (to O.I.), and the Har-
old and Ronna Cooper Family (to O.I.).
Received: April 12, 2013
Revised: April 1, 2014
Accepted: May 9, 2014
Published: June 5, 2014
REFERENCES
Barker, R.A., Barrett, J., Mason, S.L., and Bjo¨rklund, A. (2013). Fetal dopami-
nergic transplantation trials and the future of neural grafting in Parkinson’s dis-
ease. Lancet Neurol. 12, 84–91.
Ciliax, B.J., Drash, G.W., Staley, J.K., Haber, S., Mobley, C.J., Miller, G.W.,
Mufson, E.J., Mash, D.C., and Levey, A.I. (1999). Immunocytochemical
localization of the dopamine transporter in human brain. J. Comp. Neurol.
409, 38–56.
Cooper, O., Astradsson, A., Hallett, P., Robertson, H., Mendez, I., and Isacson,
O. (2009). Lack of functional relevance of isolated cell damage in transplants of
Parkinson’s disease patients. J. Neurol. 256 (Suppl 3), 310–316.
Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L.,
Spencer, B., Masliah, E., and Lee, S.J. (2009). Inclusion formation and
neuronal cell death through neuron-to-neuron transmission of alpha-synu-
clein. Proc. Natl. Acad. Sci. USA 106, 13010–13015.
Detmer, S.A., and Chan, D.C. (2007). Functions and dysfunctions of mitochon-
drial dynamics. Nat. Rev. Mol. Cell Biol. 8, 870–879.
Ding, Z.T., Wang, Y., Jiang, Y.P., Hashizume, Y., Yoshida, M., Mimuro, M., In-
agaki, T., and Iwase, T. (2006). Characteristics of alpha-synucleinopathy in
centenarians. Acta Neuropathol. 111, 450–458.
Evans, J.R., Mason, S.L., and Barker, R.A. (2012). Current status of clinical
trials of neural transplantation in Parkinson’s disease. Prog. Brain Res. 200,
169–198.
Exner, N., Lutz, A.K., Haass, C., and Winklhofer, K.F. (2012). Mitochondrial
dysfunction in Parkinson’s disease: molecular mechanisms and pathophysio-
logical consequences. EMBO J. 31, 3038–3062.
Gao, H.M., Kotzbauer, P.T., Uryu, K., Leight, S., Trojanowski, J.Q., and Lee,
V.M. (2008). Neuroinflammation and oxidation/nitration of alpha-synuclein
linked to dopaminergic neurodegeneration. J. Neurosci. 28, 7687–7698.
Hantraye, P., Brownell, A.L., Elmaleh, D., Spealman, R.D., Wu¨llner, U., Brow-
nell, G.L., Madras, B.K., and Isacson, O. (1992). Dopamine fiber detection
by [11C]-CFT and PET in a primate model of parkinsonism. Neuroreport 3,
265–268.
Isacson, O., and Mendez, I. (2010). Being too inclusive about synuclein inclu-
sions. Nat. Med. 16, 960–961, author reply 961.
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi,
M., Widner, H., Rehncrona, S., Brundin, P., Bjo¨rklund, A., et al. (2014). Long-
term clinical outcome of fetal cell transplantation for Parkinson disease: two
case reports. JAMA Neurol. 71, 83–87.
Klos, K.J., Ahlskog, J.E., Josephs, K.A., Apaydin, H., Parisi, J.E., Boeve, B.F.,
DeLucia, M.W., and Dickson, D.W. (2006). Alpha-synuclein pathology in the
spinal cords of neurologically asymptomatic aged individuals. Neurology 66,
1100–1102.
Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., and Olanow, C.W.
(2008). Lewy body-like pathology in long-term embryonic nigral transplants
in Parkinson’s disease. Nat. Med. 14, 504–506.
Kraytsberg, Y., Kudryavtseva, E., McKee, A.C., Geula, C., Kowall, N.W., and
Khrapko, K. (2006). Mitochondrial DNA deletions are abundant and cause
functional impairment in aged human substantia nigra neurons. Nat. Genet.
38, 518–520.
Kurowska, Z., Englund, E., Widner, H., Lindvall, O., Li, J.-Y., and Brundin, P.
(2011). Signs of degeneration in 12-22-year old grafts of mesencephalic dopa-
mine neurons in patients with Parkinson’s disease. J. Parkinsons Dis. 1, 83–92.
Larsson, N.G. (2010). Somaticmitochondrial DNAmutations inmammalian ag-
ing. Annu. Rev. Biochem. 79, 683–706.
Li, J.Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T.,
Quinn, N.P., Rehncrona, S., Bjo¨rklund, A., et al. (2008). Lewy bodies in grafted
neurons in subjects with Parkinson’s disease suggest host-to-graft disease
propagation. Nat. Med. 14, 501–503.
Ma, Y., Tang, C., Chaly, T., Greene, P., Breeze, R., Fahn, S., Freed, C., Dha-
wan, V., and Eidelberg, D. (2010). Dopamine cell implantation in Parkinson’s
disease: long-term clinical and (18)F-FDOPA PET outcomes. J. Nucl. Med.
51, 7–15.
Mendez, I., Sanchez-Pernaute, R., Cooper, O., Vin˜uela, A., Ferrari, D., Bjo¨r-
klund, L., Dagher, A., and Isacson, O. (2005). Cell type analysis of functional
fetal dopamine cell suspension transplants in the striatum and substantia nigra
of patients with Parkinson’s disease. Brain 128, 1498–1510.
Mendez, I., Vin˜uela, A., Astradsson, A., Mukhida, K., Hallett, P., Robertson, H.,
Tierney, T., Holness, R., Dagher, A., Trojanowski, J.Q., and Isacson, O. (2008).
Dopamine neurons implanted into people with Parkinson’s disease survive
without pathology for 14 years. Nat. Med. 14, 507–509.
Mikolaenko, I., Pletnikova, O., Kawas, C.H., O’Brien, R., Resnick, S.M., Crain,
B., and Troncoso, J.C. (2005). Alpha-synuclein lesions in normal aging, Parkin-
son disease, and Alzheimer disease: evidence from the Baltimore Longitudinal
Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 64, 156–162.
Miller, G.W., Staley, J.K., Heilman, C.J., Perez, J.T., Mash, D.C., Rye, D.B., and
Levey, A.I. (1997). Immunochemical analysis of dopamine transporter protein
in Parkinson’s disease. Ann. Neurol. 41, 530–539.
Nirenberg, M.J., Chan, J., Vaughan, R.A., Uhl, G.R., Kuhar, M.J., and Pickel,
V.M. (1997). Immunogold localization of the dopamine transporter: an ultra-
structural study of the rat ventral tegmental area. J. Neurosci. 17, 5255–5262.CPolitis, M., Wu, K., Loane, C., Quinn, N.P., Brooks, D.J., Rehncrona, S., Bjor-
klund, A., Lindvall, O., and Piccini, P. (2010). Serotonergic neurons mediate
dyskinesia side effects in Parkinson’s patients with neural transplants. Sci.
Transl. Med. 2, 38ra46.
Politis, M., Wu, K., Loane, C., Quinn, N.P., Brooks, D.J., Oertel, W.H., Bjor-
klund, A., Lindvall, O., and Piccini, P. (2012). Serotonin neuron loss and non-
motor symptoms continue in Parkinson’s patients treated with dopamine
grafts. Sci. Transl. Med. 4, 128ra141.
Saito, Y., Ruberu, N.N., Sawabe, M., Arai, T., Kazama, H., Hosoi, T., Yamanou-
chi, H., andMurayama, S. (2004). Lewy body-related alpha-synucleinopathy in
aging. J. Neuropathol. Exp. Neurol. 63, 742–749.
Sanders, L.H., Laganie`re, J., Cooper, O., Mak, S.K., Vu, B.J., Huang, Y.A., Pa-
schon, D.E., Vangipuram, M., Sundararajan, R., Urnov, F.D., et al. (2014).
LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural
cells from Parkinson’s disease patients: reversal by gene correction. Neuro-
biol. Dis. 62, 381–386.
Sherer, T.B., Kim, J.H., Betarbet, R., and Greenamyre, J.T. (2003). Subcutane-
ous rotenone exposure causes highly selective dopaminergic degeneration
and alpha-synuclein aggregation. Exp. Neurol. 179, 9–16.
Wakisaka, Y., Furuta, A., Tanizaki, Y., Kiyohara, Y., Iida, M., and Iwaki, T.
(2003). Age-associated prevalence and risk factors of Lewy body pathology
in a general population: the Hisayama study. Acta Neuropathol. 106, 374–382.
Wang, X., Su, B., Zheng, L., Perry, G., Smith, M.A., and Zhu, X. (2009). The role
of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s dis-
ease. J. Neurochem. 109 (Suppl 1), 153–159.ell Reports 7, 1755–1761, June 26, 2014 ª2014 The Authors 1761
